| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Cheif Financial Officer | Common Stock | 48,091 | $38,473 | $0.8000 | 01 Mar 2023 | Direct |
| Inhibikase Therapeutics, Inc. | Cheif Financial Officer | Stock Option (right to buy) | 90,000 | 01 Mar 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 01 Mar 2023 | 1 | $0 | 4 | Cheif Financial Officer | 03 Mar 2023, 16:00 |
| IKT | Inhibikase Therapeutics, Inc. | 19 May 2022 | 1 | +$2,543 | 4 | Chief Financial Officer | 23 May 2022, 16:54 |
| IKT | Inhibikase Therapeutics, Inc. | 07 Mar 2022 | 1 | $0 | 4 | Chief Financial Officer | 21 Mar 2022, 16:05 |
| IKT | Inhibikase Therapeutics, Inc. | 07 Mar 2022 | 1 | $0 | 4 | Cheif Financial Officer | 09 Mar 2022, 19:22 |